Egyszerű nézet

dc.contributor.author Petke, Zsolt
dc.contributor.author Csorba J
dc.contributor.author Mészáros, Judit
dc.contributor.author Vingender, István
dc.contributor.author Farkas, Judit
dc.contributor.author Demetrovics, Zsolt
dc.contributor.author Kovács, Zsuzsanna
dc.contributor.author Menczel, Zsuzsanna
dc.contributor.author Pataki Z
dc.contributor.author Simor, Péter
dc.contributor.author Havasi A
dc.contributor.author Melles K
dc.contributor.author Marvanykovi F
dc.contributor.author Rácz, József
dc.date.accessioned 2015-05-15T11:29:10Z
dc.date.available 2015-05-15T11:29:10Z
dc.date.issued 2012
dc.identifier 84862893123
dc.identifier.citation pagination=7-17; journalVolume=14; journalIssueNumber=1; journalTitle=NEUROPSYCHOPHARMACOLOGIA HUNGARICA;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/1861
dc.description.abstract Aims: The main target of our research was to measure the changes in psychological symptoms (anxiety, depression, craving) of patients receiving buprenorphine-naloxone substitution treatment for six months, and the evaluation of the changes using the clients' dependency parameters (ASI). Methods: The level of dependency was investigated using the Addicton Severity Index (ASI). The psychiatric symptoms related to Axis I and II disorders were examined using the Structured Clinical Interview for DSM-IV, SCID I and SCID II. The degree of craving was measured using the Heroin Craving Questionnaire, the assessment of the symptoms of depression using BDI and HAM-D, recorded by the medical attendant of the patient. To survey the extent of anxiety, we used STAI-S, and HAM-A. All patients receiving Suboxone therapy in Hungary between November 2007 and April 2008 were included in the study (n=80). During this time, Suboxone therapy was available in 6 locations. Results: We found significant improvement in almost all observed fields of behavioural and symptomatic dimensions during the first month. The only exception was the dimension of subsistence/livelihood of ASI, the changes were only at the tendency level. During the next five months of therapy, there was no further sign of improvement or decline in the observed fields, the only exception was again the subsistence/livelihood dimension of the ASI. Conclusions: Our results indicate that buprenorphine/naloxone treatment is a promising possibility for patients in need of opiate-substitution treatment.
dc.relation.ispartof urn:issn:1419-8711
dc.title Buprenorphin/naloxon szubsztitúció alatt álló ópiátfüggők pszichoszociális tüneteinek változásai hathónapos terápia során [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy]
dc.type Journal Article
dc.date.updated 2015-05-15T10:34:31Z
dc.language.rfc3066 hu
dc.identifier.mtmt 1938791
dc.identifier.pubmed 22427466
dc.contributor.department Budapesti Műszaki és Gazdaságtudományi Egyetem
dc.contributor.department BME/TTK/Kognitív Tudományi Tanszék
dc.contributor.department SE/ETK/AEI/Addiktológiai Tanszék
dc.contributor.department SE/ETK/Alapozó Egészségtudományi Intézet
dc.contributor.department SE/ETK/AEI/Alkalmazott Pszichológiai Tanszék
dc.contributor.institution Budapesti Műszaki és Gazdaságtudományi Egyetem
dc.contributor.institution Semmelweis Egyetem


Kapcsolódó fájlok:

A fájl jelenleg csak egyetemi IP címről érhető el.

Megtekintés/Megnyitás

Ez a rekord az alábbi gyűjteményekben szerepel:

Egyszerű nézet